Lexaria Bioscience Corp (LEXX)

[Bluetikiman]

It's an interesting question for sure. I think long term that CBD/THC applications should be the biggest market, as most states with recreational use have limits on total amount allowed per edible (100 mg usually). That means that, theoretically, Lexaria licensee's could be selling edibles that adhere to the regulations, while increasing the effects of the same dosage by 50% or more. This means consumers are getting way more bang for their buck, especially if they are priced the same as current industry leaders (like kiva and kushy punch)

However, from a purely stock price standpoint, I think a nicotine deal would be massive. It would move the stock from a "weed play" to more of a biotech/pharma play, by proving that the tech can be applied across a broad spectrum. Furthermore, big tobacco has deep pockets. Phillip Morris alone is spending a LOT of money looking for healthier alternatives to cigarettes.

Finally, and in a similar vein to the nicotine application, a deal with a pharma industry company for NSAIDS could be huge. Reducing dosage while keeping effects would be a game changer, as NSAID use is really terrible for one's stomach lining and is hard for the body to process. This also accomplishes the same goal of establishing Lexaria as a true biotech play (think GW Pharma).

Just my two cents